Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trabectedin + tTF-NGR |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trabectedin | Yondelis | ET-743 | Chemotherapy - Alkylating 18 | Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov). |
tTF-NGR | tTF-NGR is a fusion protein that comprises truncated tissue factor (tTF) linked to a C-terminal NGR peptide, which binds CD13 and potentially inhibits tumor vasculature and blood flow and reduces tumor growth (PMID: 32517329, PMID: 29110838). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05597917 | Phase III | Trabectedin Trabectedin + tTF-NGR | tTF-NGR Randomized Study - STS (TRABTRAP) | Recruiting | DEU | AUT | 0 |